title: Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients.
abstract: In order to assess the efficacy of gemfibrozil on lipid and haemostatic parameters in patients with plurimetabolic syndrome, a multicenter double-blind placebo controlled, parallel study was carried out in 56 patients with primary hypertriglyceridemia and glucose intolerance. These patients had elevated PAI activity and antigen and t-PA antigen levels at rest and after venous occlusion. Gemfibrozil reduced plasma triglyceride levels (P<0.001), whereas it increased free fatty acids (P<0.05) and high density lipoprotein cholesterol levels (P<0.05). In those patients reaching normalization of plasma triglyceride levels (triglyceride reduction > or =50%) (n=15), insulin levels (P<0.05) as well as the insulin resistance index were reduced by gemfibrozil treatment, suggesting an improvement of the insulin resistance index in this patient subgroup. Gemfibrozil treatment did not affect plasma fibrinolysis or fibrinogen levels, despite marked reduction of plasma triglycerides and improvement of the insulin sensitivity associated with triglyceride normalization.
authors.affiliation: Institute of Pharmacological Sciences and E. Grossi Paoletti Center, Via Balzaretti, 9, University of Milan, 20133, Milan, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Mussoni
authors.forename: L
authors.initials: L
authors.lastname: Mannucci
authors.forename: C
authors.initials: C
authors.lastname: Sirtori
authors.forename: F
authors.initials: F
authors.lastname: Pazzucconi
authors.forename: G
authors.initials: G
authors.lastname: Bonfardeci
authors.forename: C
authors.initials: C
authors.lastname: Cimminiello
authors.forename: A
authors.initials: A
authors.lastname: Notarbartolo
authors.forename: V
authors.initials: V
authors.lastname: Scafidi
authors.forename: G
authors.initials: G
authors.lastname: Bittolo Bon
authors.forename: P
authors.initials: P
authors.lastname: Alessandrini
authors.forename: G
authors.initials: G
authors.lastname: Nenci
authors.forename: P
authors.initials: P
authors.lastname: Parise
authors.forename: L
authors.initials: L
authors.lastname: Colombo
authors.forename: T
authors.initials: T
authors.lastname: Piliego
authors.forename: E
authors.initials: E
authors.lastname: Tremoli
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D004311:Double-Blind Method; D005230:Fatty Acids, Nonesterified / Q000097:blood; D015248:Gemfibrozil / Q000627:therapeutic use*; D005951:Glucose Tolerance Test; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D015228:Hypertriglyceridemia / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged
chemical_list: D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D000960:Hypolipidemic Agents; D007328:Insulin; D015248:Gemfibrozil